H.C. Wainwright initiated coverage of Fractyl Health (GUTS) with a Buy rating and $9 price target Fractyl is a clinical stage biotechnology company focused on developing one-time, long-lasting, disease-modifying treatments for obesity and type 2 diabetes, targeting the gut and the pancreas as the root-cause organs of metabolic diseases, the analyst tells investors in a research note. The firm says Fractyl’s Revita and Rejuva have exhibited sustained weight loss and glucose control efficacy, with favorable safety and tolerability profiles.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health Appoints New Directors Amid Leadership Changes
- Fractyl Health appoints Christopher Thompson, Ian Sheffield to board
- Fractyl Health initiated with a Buy at Ladenburg
- Fractyl Health price target lowered to $6 from $12 at Canaccord
- Fractyl Health’s Earnings Call: Strategic Gains Amid Financial Challenges